Esbriet

Active Ingredient(s): Pirfenidone
FDA Approved: * October 15, 2014
Pharm Company: * INTERMUNE INC
Category: Lungs (Pulmonary)

Pirfenidone is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II. It was first approved in Japan for the treatment of patients with idiopathic pulmonary fibrosis after clinical trials, under the trade name of Pirespa by Shionogi, in 2008. It was approved for use in the European Union in 2011,[2][3] in Canada in 2012, and in... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Esbriet 267 mg Oral Capsule
NDC: 50242-121
Labeler:
Genentech, Inc.
Esbriet 267 mg Oral Tablet, Coated
NDC: 50242-122
Labeler:
Genentech, Inc.
Esbriet 801 mg Oral Tablet, Coated
NDC: 50242-123
Labeler:
Genentech, Inc.
Esbriet 267 mg Oral Capsule
NDC: 64116-121
Labeler:
Intermune, Inc.